Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 134 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: mitomycin Clear all
Active, not recruiting Phase 3 Interventional

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

NCT03775265
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Atezolizumab, Biopsy of Bladder, Cisplatin, Computed Tomography, Cystoscopy, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Quality-of-Life Assessment, Radiation Therapy, Survey Administration, Transurethral Resection of Bladder Tumor
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
365
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 273 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 20, 2026, 11:31 PM EDT
Completed Phase 3 Interventional Results available

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study

NCT02793128
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Interventions
UGN-101 instillations
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 20, 2026, 11:31 PM EDT
Recruiting Phase 1Phase 2 Interventional

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

NCT06704191
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
Interventions
BCG Solution, Cystoscopy, Docetaxel, Gemcitabine, Home Health Encounter, Mitomycin, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 11:31 PM EDT
Completed Phase 3 Interventional

Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer

NCT00002507
View directory record Official record
Conditions
Carcinoma of Unknown Primary, Head and Neck Cancer
Interventions
mitomycin C, porfiromycin, brachytherapy, radiation therapy
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2002
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 20, 2026, 11:31 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery

NCT01115517
View directory record Official record
Conditions
Pterygium
Interventions
Bevacizumab, Mitomycin C
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 20, 2026, 11:31 PM EDT
Recruiting Phase 3 Interventional

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

NCT07271355
View directory record Official record
Conditions
Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Magnetic Resonance Imaging, Mitomycin, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Goodyear, Arizona • Duarte, California • Irvine, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 11:31 PM EDT
Completed Phase 2 Interventional Results available

Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

NCT03092518
View directory record Official record
Conditions
Gastric Adenocarcinoma, Esophagogastric Junction, Gastric Cancer
Interventions
Surgery, Cisplatin, Mitomycin C, Sodium Thiosulfate, Tumor Biopsy, CT C/A/P, PET-CT, MRI, EKG
Procedure · Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 20, 2026, 11:31 PM EDT
Not listed Phase 4 Interventional

A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopic Patients With Treatments to Optimize the Ocular Surface Before Implantation

NCT03126877
View directory record Official record
Conditions
Presbyopia
Interventions
Mitomycin C, Raindrop Near Vision Inlay
Drug · Device
Lead sponsor
Whitten Laser Eye
Other
Eligibility
41 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 20, 2026, 11:31 PM EDT
Active, not recruiting Phase 2 Interventional

ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis

NCT01815359
View directory record Official record
Conditions
Appendix Cancer, Colorectal Cancer
Interventions
Cytoreductive Surgery, HIPEC with Mitomycin-C, EPIC with FUDR and Leucovorin
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
9
States / cities
Miami, Florida • St Louis, Missouri • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 11:31 PM EDT
Recruiting Phase 3 Interventional

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

NCT07566156
View directory record Official record
Conditions
Urothelial Cancer, Urinary Bladder Neoplasms
Interventions
Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy, Cisplatin, Fluorouracil, Mitomycin C, Gemcitabine, Pembrolizumab
Drug · Radiation
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
19
States / cities
Little Rock, Arkansas • Santa Barbara, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 11:31 PM EDT
Completed Phase 2 Interventional

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

NCT02710734
View directory record Official record
Conditions
Urothelial Carcinoma of the Bladder
Interventions
Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Intensity modulated radiation therapy (IMRT), Transurethral Resection of Bladder tumor, 5-FU, Mitomycin C
Drug · Radiation · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 11:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Ranibizumab With Mitomycin C During Trabeculectomy

NCT00661583
View directory record Official record
Conditions
Glaucoma
Interventions
Ranibizumab, Ranibizumab and MMC, MMC
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Oct 20, 2026, 11:31 PM EDT
Terminated Phase 2 Interventional Results available

A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma

NCT02994251
View directory record Official record
Conditions
Unresectable Intrahepatic Cholangiocarcinoma
Interventions
gemcitabine, Cisplatin, Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 20, 2026, 11:31 PM EDT
Completed Phase 4 Interventional

Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin C

NCT00346489
View directory record Official record
Conditions
Glaucoma
Interventions
5-fluorouracil, Mitomycin C
Drug
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 20, 2026, 11:31 PM EDT
Completed Not applicable Interventional Results available

Tube Versus Trabeculectomy (TVT) Study

NCT00306852
View directory record Official record
Conditions
Glaucoma
Interventions
Baerveldt implant, Trabeculectomy with mitomycin C
Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 85 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 20, 2026, 11:31 PM EDT
Withdrawn Phase 2 Interventional

Efficacy of Topical Mitomycin C for Complex Benign Esophageal Anastomotic Strictures

NCT04037072
View directory record Official record
Conditions
Esophageal Stenosis, Anastomotic Stenosis
Interventions
Mitomycin C, Control
Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 20, 2026, 11:31 PM EDT
Completed Phase 4 Interventional

Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Glaucoma Filtering Surgery

NCT01440751
View directory record Official record
Conditions
Glaucoma
Interventions
Use of ologen Collagen Matrix in trabeculectomy (ologen), Use of Mitomycin-C (MMC) in trabeculectomy
Device · Drug
Lead sponsor
Aeon Astron Europe B.V.
Industry
Eligibility
30 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Rogers, Arkansas • Chicago, Illinois • Newark, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 20, 2026, 11:31 PM EDT
Completed Phase 2 Interventional Results available

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

NCT03617913
View directory record Official record
Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8, Stage II Urethral Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Urethral Urothelial Carcinoma
Interventions
Avelumab, Cisplatin, Fluorouracil, Mitomycin, Quality-of-Life Assessment, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 20, 2026, 11:31 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

NCT05902533
View directory record Official record
Conditions
Anal Cancer
Interventions
Radiation (reduced elective nodal dose (30.6 Gy), Capecitabine, Mitomycin c
Radiation · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbus, Ohio • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 20, 2026, 11:31 PM EDT
Recruiting Phase 2 Interventional

Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors

NCT07671534
View directory record Official record
Conditions
Solid Tumor Cancer
Interventions
Gemcitabine, Mitomycin C, Thalidomide
Drug
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 20, 2026, 11:31 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

NCT03558503
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 20, 2026, 11:31 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

NCT04216290
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8
Interventions
Biopsy of Bladder, Biospecimen Collection, Cisplatin, Computed Tomography, Cystoscopy, Durvalumab, Fluorouracil, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Mitomycin, Patient Observation, Radiation Therapy
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
216
States / cities
Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 153 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 11:31 PM EDT
Completed Phase 2 Interventional

Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery

NCT00949182
View directory record Official record
Conditions
Liver Cancer
Interventions
sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C, laboratory biomarker analysis
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 20, 2026, 11:31 PM EDT
Completed Phase 1 Interventional

Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors

NCT00003710
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, mitomycin C
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Oct 20, 2026, 11:31 PM EDT